A Phase 4 interventional study of Tadalafil and Sildenafil Citrate in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 45 sites in 8 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-19.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.
Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 5th largest by enrollment of the 56 interventional ones that give a count, is one of 3 that started in 2010, is one of 26 in phase 4, and was the 27th registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:
Surgical Outcomes Research Centre (SOuRCe) · Sites in Australia
Ages 18+ · Men only
Al-Azhar University · Sites in Egypt
Ages 18–70 · Men only
Beni-Suef University · Sites in Egypt
Ages 30–70 · Men only
Mansoura University · Sites in Egypt
Ages 21+ · Men only
Aswan University Hospital · Sites in Egypt
Ages 21+ · Men only
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 21 · Phase 4 26
First in 2002; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 770 is above the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 199 across the 56 interventional studies. Of the 42 that completed or were terminated, 13 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 57 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
28 studies in Erectile Dysfunction by Eli Lilly and Company: none open now, none under way, none of them phase 3. Of 28 finished, 14 (50%) have results posted.
Among the 28 studies in Erectile Dysfunction by Eli Lilly and Company, this one is the 4th largest by enrollment, is one of 3 that started in 2010, is one of 12 in phase 4, and was the 21st registered.
Eli Lilly and Company’s Erectile Dysfunction studies by the year they started, since 2002.
3 of the studies testing tadalafil in Erectile Dysfunction that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07642505Beni-Suef UniversityL-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction | 2026-11 |
| NCT07391579Mansoura UniversityDaily Tadalafil 5 mg Combined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfunction in PDE-5I Non Responder Patients | 2026-12 |
| NCT07753720Al-Azhar UniversityDaily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies testing tadalafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 28 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate if treatment in erectile dysfunction with a long-acting drug (Tadalafil) taken once a day or taken as needed results in a longer treatment adherence and better long term outcomes (over 24 weeks), compared with a short-acting drug (Sildenafil Citrate) taken as needed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 milligrams (mg) or 20 mg on demand
Drug: Tadalafil
5 mg or 2.5 mg once a day
Drug: Tadalafil
50 mg, 100 mg, or 25 mg on demand
Drug: Sildenafil Citrate
Administered orally for 24 weeks.
Also known as: Cialis, LY450190
Administered orally for 24 weeks.
Time to Discontinuation of Randomized Treatment
Time to discontinuation of randomized treatment was defined as the number of days from randomization until the day the participant discontinued the randomized treatment. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered switching of treatment. This outcome measure was estimated using the Kaplan-Meier product-limit method.
Time frame: Baseline up to 334 days
Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Erectile Function (EF) Domain
Self-reported EF score over past 4 weeks. Items 1-5 scores range from 0 (no sexual activity) to 5 (high EF). Item 15 score ranges from 1 (very low confidence to get/keep erection) to 5 (very high confidence). Total scores range from 1 to 30; lower scores denote greater erectile dysfunction severity. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.
Time frame: Baseline, 4, 8, 16, and 24 weeks
Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Orgasmic Function Domain
Self-reported orgasmic function on the IIEF over past 4 weeks and consists of 2 questions (items 9 and 10). Each question is rated on a scale from 0 (no sexual stimulation) to 5 (almost always/always). Total scores range from 0 to 10; lower scores represent lower orgasmic function. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.
Time frame: Baseline, 4, 8, 16, and 24 weeks
Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Sexual Desire Domain
Self-reported sexual desire on IIEF over past 4 weeks; comprises 2 questions (items 11 and 12). Each question rated on a scale from 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). Total scores range: 2 to 10; lower numerical scores denote lower sexual desire. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.
Time frame: Baseline, 4, 8, 16, and 24 weeks
Change From Baseline to 4, 8, 16 and 24 Weeks of the Sexual Encounter Profile (SEP)
Participant-assessed diary. Has 5 questions (Question\[Q\]1:erection achievement, Q2:successful penetration, Q3:successful intercourse, Q4:satisfied with erection, and Q5:satisfied with sexual experience) for each sexual encounter made over specified period of time. SEP Q1-Q5 scores determined as percentage of 'Yes' responses to each of 5 questions out of all sexual attempts recorded during the time period. Least Squares Mean changes from baseline to endpoint for each visit from a repeated measures analysis included terms for baseline score, treatment group, country, visit, and visit\*treatment.
Time frame: Baseline, 4, 8, 16, and 24 weeks
Global Assessment Questions (GAQ)
The GAQ consists of 2 Yes/No/No Response (No Respo) questions. GAQ Question (Q)1: Has the treatment you have been taking during this study improved your erections? GAQ Q2: Has the treatment improved your ability to engage in sexual activity?
Time frame: 24 weeks
Number of Treatment Switches
The number of times participants switched erectile dysfunction medication within the 3 treatments being studied (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand).
Time frame: Baseline through 24 weeks
Patterns of Erectile Dysfunction Treatment Change
Results are reported as the number of participants per sequence of study medications (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) that were taken as a result of switching treatments. The Other Treatment Sequence reports the number of participants per sequence of study medications that were taken as a result of switching treatments more than once. The number of participants who did not switch is also reported.
Time frame: Baseline through 24 weeks
Reasons for Discontinuation of Randomized Erectile Dysfunction Treatment
The reported reasons for a decision to discontinue from initial randomized treatment prior to Week 24 are reported. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered as switching of treatment.
Time frame: Baseline through 24 weeks
Number of Days From the 8-Week Study Visit to the Time the Participant Discontinues From All Phosphodiesterase Type 5 (PDE5) Inhibitor Treatments
The differences in time between the 8-week time point and the discontinuation of all study treatments (that is, discontinuation from the study and not switching to another treatment) are reported by the median (95% confidence interval). Duration was measured as the number of days from Week 8 to the date of the last dose of the study drug. This outcome measure was estimated using the Kaplan-Meier product-limit method.
Time frame: 8 weeks up to 334 days
Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Intercourse Satisfaction Domain
Self-reported intercourse satisfaction score over past 4 weeks (1 intercourse attempt item, 2 intercourse satisfaction items). Each item range: 0 (no intercourse attempts/no satisfaction) to 5 (more attempts/high satisfaction). Total scores range: 0-15; lower scores=lower intercourse satisfaction. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.
Time frame: Baseline, 4, 8, 16, and 24 weeks
Change From Baseline to 4, 8, 16 and 24 Weeks of the International Index of Erectile Function (IIEF) Overall Satisfaction Domain
Self-reported overall satisfaction on the IIEF over past 4 weeks and consists of 2 questions (items 13 and 14), each rated on a scale from 1 (very dissatisfied) to 5 (very satisfied). Total scores range from 2 to 10; lower numerical scores represent lower overall satisfaction. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.
Time frame: Baseline, 4, 8, 16, and 24 weeks
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire at 4, 8, 16, and 24 Weeks
The participant questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score was obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), then multiplying by 25, thus obtaining a score range from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction). Least Squares Mean changes were adjusted for treatment group, country, visit, and visit\*treatment.
Time frame: 4, 8, 16, and 24 weeks
Change From Baseline to 24 Week Endpoint of the Sexual Self-Confidence, Spontaneity, and Time Concerns Domains (23-items) of the Psychological and Interpersonal Relationships Scale (PAIRS)
The PAIRS is a 23-item scale that assesses broader psychological/interpersonal outcomes associated with erectile dysfunction and its treatment. Each question is rated on a Likert scale from 1 (strongly disagree) to 4 (strongly agree). The scale consists of 3 domains: Sexual Self-Confidence (items 1-6), Spontaneity domain (items 7-15), and Time Concerns (items 16-23). The average domain score for each domain was calculated by adding the nonmissing items for the respective domain, then dividing by the number of nonmissing items for the respective domain. Each average domain score ranged from 1 to 4. Higher scores represent the following: greater sexual self-confidence (better outcome); greater spontaneity (better outcome); higher time concerns (worse outcome). The Least Squares Mean changes were adjusted for treatment group, country, baseline IIEF-EF severity, baseline domain score, and baseline domain score\*treatment (if p\<0.10).
Time frame: Baseline, 24 weeks
Change From Baseline to 4, 8, 16, and 24 Weeks of the Sexual Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire
SEAR assesses psychosocial outcomes in men with erectile dysfunction. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. Transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes adjusted for baseline score, treatment group, country, visit, and visit\*treatment.
Time frame: Baseline, 4, 8, 16, and 24 weeks
Change From Baseline to 4, 8, 16, and 24 Weeks of the Confidence Domain of the Self-Esteem and Relationship (SEAR) Questionnaire
SEAR assesses psychosocial outcomes in men with erectile dysfunction. Confidence domain measures improvement in confidence; 2 subscales (6 items: Self-Esteem \[items 9-12\]; Overall Relationship \[items 13-14\]). Each item range: 1 (Never) to 5 (Always); item 11 reverse scored. Domain score=sum of domain's respective items, then transformed into 0 (least favorable) to 100 (most favorable) scale. Transformed score=100x\[(actual raw score-lowest possible raw score)/possible raw score range\]. Least Squares Mean change adjusted for baseline score, treatment group, country, visit, and visit\*treatment.
Time frame: Baseline, 4, 8, 16, and 24 weeks
Change From Baseline to 4, 8, 16, and 24 Weeks of the Self Esteem Domain of the Self-Esteem and Relationship (SEAR) Questionnaire
SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Self-Esteem domain consists of 4 items (items 9-12), each rated on a scale of 1 (Never) to 5 (Always). Item 11 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit\*treatment.
Time frame: Baseline, 4, 8, 16, and 24 weeks
Change From Baseline to 4, 8, 16, and 24 Weeks of the Overall Relationship Domain of the Self-Esteem and Relationship (SEAR) Questionnaire
SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Overall Relationship domain consists of 2 items (items 13-14), each rated on a scale of 1 (Never) to 5 (Always). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit\*treatment.
Time frame: Baseline, 4, 8, 16, and 24 weeks
| Milestone | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Started | 252 | 257 | 261 |
| Received at least 1 dose of study drug | 250 | 257 | 260 |
| Completed | 220 | 228 | 214 |
| Not completed | 32 | 29 | 47 |
| Withdrew: Adverse event | 6 | 5 | 7 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 9 | 13 |
| Withdrew: Entry criteria not met | 1 | 0 | 0 |
| Withdrew: Protocol violation | 7 | 7 | 9 |
| Withdrew: Withdrawal by subject | 6 | 6 | 16 |
| Withdrew: Physician decision | 3 | 1 | 1 |
| Withdrew: Lack of efficacy | 3 | 1 | 1 |
Time to discontinuation of randomized treatment was defined as the number of days from randomization until the day the participant discontinued the randomized treatment. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered switching of treatment. This outcome measure was estimated using the Kaplan-Meier product-limit method.
| days | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Time to Discontinuation of Randomized Treatment | NA (187 to NA) | 130 (113 to NA) | 67 (64 to 77) |
Self-reported EF score over past 4 weeks. Items 1-5 scores range from 0 (no sexual activity) to 5 (high EF). Item 15 score ranges from 1 (very low confidence to get/keep erection) to 5 (very high confidence). Total scores range from 1 to 30; lower scores denote greater erectile dysfunction severity. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.
| units on a scale | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Change from Baseline to Week 4 | 7.92 ± 0.44 | 8.60 ± 0.43 | 8.86 ± 0.43 |
| Change from Baseline to Week 8 (n=231, 232, 232) | 8.98 ± 0.45 | 9.08 ± 0.45 | 9.70 ± 0.44 |
| Change from Baseline to Week 16 (n=167, 146, 101) | 10.60 ± 0.41 | 9.93 ± 0.42 | 10.56 ± 0.45 |
| Change from Baseline to Week 24 (n=141, 116, 81) | 10.70 ± 0.43 | 10.01 ± 0.45 | 11.05 ± 0.49 |
Self-reported orgasmic function on the IIEF over past 4 weeks and consists of 2 questions (items 9 and 10). Each question is rated on a scale from 0 (no sexual stimulation) to 5 (almost always/always). Total scores range from 0 to 10; lower scores represent lower orgasmic function. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.
| units on a scale | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Change from Baseline to Week 4 | 1.64 ± 0.16 | 1.75 ± 0.16 | 1.92 ± 0.16 |
| Change from Baseline to Week 8 (n=231, 232, 232) | 1.77 ± 0.16 | 2.08 ± 0.16 | 2.26 ± 0.16 |
| Change from Baseline to Week 16 (n=167, 146, 101) | 2.37 ± 0.15 | 2.25 ± 0.16 | 2.66 ± 0.17 |
| Change from Baseline to Week 24 (n=141, 116, 81) | 2.55 ± 0.15 | 2.48 ± 0.16 | 2.62 ± 0.18 |
Self-reported sexual desire on IIEF over past 4 weeks; comprises 2 questions (items 11 and 12). Each question rated on a scale from 1 (almost never or low/no sexual desire) to 5 (almost always or very high sexual desire). Total scores range: 2 to 10; lower numerical scores denote lower sexual desire. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.
| units on a scale | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Change from Baseline to 4 Weeks | 0.77 ± 0.10 | 0.75 ± 0.10 | 0.69 ± 0.10 |
| Change from Baseline to 8 Weeks (n=230, 232, 232) | 0.96 ± 0.11 | 0.90 ± 0.11 | 0.87 ± 0.11 |
| Change from Baseline to 16 Weeks (n=167, 146, 101) | 1.15 ± 0.12 | 0.87 ± 0.12 | 1.07 ± 0.14 |
| Change from Baseline to 24 Weeks (n=140, 117, 81) | 1.19 ± 0.12 | 0.78 ± 0.13 | 1.29 ± 0.14 |
Participant-assessed diary. Has 5 questions (Question\[Q\]1:erection achievement, Q2:successful penetration, Q3:successful intercourse, Q4:satisfied with erection, and Q5:satisfied with sexual experience) for each sexual encounter made over specified period of time. SEP Q1-Q5 scores determined as percentage of 'Yes' responses to each of 5 questions out of all sexual attempts recorded during the time period. Least Squares Mean changes from baseline to endpoint for each visit from a repeated measures analysis included terms for baseline score, treatment group, country, visit, and visit\*treatment.
| percentage of "yes" responses | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Q1:Change from Baseline to 4 Weeks | 14.50 (11.82 to 17.18) | 18.49 (15.83 to 21.14) | 18.41 (15.77 to 21.05) |
| Q1:Change from Baseline to 8 Weeks (n=224,231,229) | 16.62 (14.05 to 19.19) | 19.88 (17.33 to 22.43) | 20.41 (17.87 to 22.96) |
| Q1:Change from Baseline to 16 Weeks (n=166,146,99) | 18.46 (16.02 to 20.89) | 19.19 (16.72 to 21.67) | 20.58 (17.90 to 23.27) |
| Q1:Change from Baseline to 24 Weeks (n=139,115,81) | 19.97 (17.78 to 22.15) | 19.60 (17.33 to 21.86) | 20.34 (17.94 to 22.74) |
| Q2:Change from Baseline to 4 Weeks | 27.48 (23.77 to 31.19) | 28.56 (24.87 to 32.24) | 29.64 (25.96 to 33.31) |
| Q2:Change from Baseline to 8 Weeks (n=224,231,229) | 31.16 (27.57 to 34.76) | 31.66 (28.09 to 35.22) | 34.08 (30.52 to 37.64) |
| Q2:Change from Baseline to 16 Weeks (n=166,146,99) | 32.76 (29.38 to 36.14) | 32.76 (29.33 to 36.20) | 36.07 (32.38 to 39.76) |
| Q2:Change from Baseline to 24 Weeks (n=139,115,81) | 35.83 (32.71 to 38.94) | 34.70 (31.48 to 37.92) | 35.93 (32.51 to 39.35) |
| Q3:Change from Baseline to 4 Weeks | 41.52 (36.79 to 46.26) | 41.76 (37.05 to 46.47) | 44.45 (39.76 to 49.13) |
| Q3:Change from Baseline to 8 Weeks (n=224,231,229) | 47.45 (42.65 to 52.26) | 44.58 (39.80 to 49.35) | 52.11 (47.36 to 56.86) |
| Q3:Change from Baseline to 16 Weeks (n=166,146,99) | 54.26 (49.86 to 58.67) | 50.62 (46.14 to 55.11) | 56.96 (52.10 to 61.82) |
| Q3:Change from Baseline to 24 Weeks (n=139,115,81) | 56.39 (51.89 to 60.89) | 53.83 (49.13 to 58.53) | 56.28 (51.18 to 61.38) |
| Q4:Change from Baseline to 4 Weeks | 49.59 (44.22 to 54.97) | 51.78 (46.44 to 57.12) | 51.45 (46.13 to 56.76) |
| Q4:Change from Baseline to 8 Weeks (n=224,231,229) | 60.86 (55.37 to 66.36) | 55.59 (50.14 to 61.05) | 59.28 (53.85 to 64.71) |
| Q4:Change from Baseline to 16 Weeks (n=166,146,99) | 66.17 (60.92 to 71.43) | 63.00 (57.64 to 68.36) | 66.48 (60.65 to 72.31) |
| Q4:Change from Baseline to 24 Weeks (n=139,115,81) | 72.67 (67.46 to 77.89) | 68.06 (62.58 to 73.54) | 69.04 (63.06 to 75.02) |
| Q5:Change from Baseline to 4 Weeks | 46.12 (40.79 to 51.46) | 45.71 (40.41 to 51.01) | 49.63 (44.35 to 54.90) |
| Q5:Change from Baseline to 8 Weeks (n=224,231,229) | 53.92 (48.46 to 59.37) | 50.06 (44.65 to 55.47) | 55.73 (50.33 to 61.13) |
| Q5:Change from Baseline to 16 Weeks (n=166,146,99) | 61.57 (56.26 to 66.88) | 54.56 (49.16 to 59.96) | 62.40 (56.55 to 68.25) |
| Q5:Change from Baseline to 24 Weeks (n=139,115,81) | 65.45 (60.29 to 70.60) | 62.17 (56.78 to 67.57) | 66.57 (60.72 to 72.42) |
The GAQ consists of 2 Yes/No/No Response (No Respo) questions. GAQ Question (Q)1: Has the treatment you have been taking during this study improved your erections? GAQ Q2: Has the treatment improved your ability to engage in sexual activity?
| participants | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Q1:Treatment improved erections? Yes | 218 | 219 | 203 |
| Q1:Treatment improved erections? No | 20 | 23 | 34 |
| Q1: Treatment improved erections? No Response | 14 | 15 | 24 |
| Q2:Treatment improved ability to engage? Yes | 209 | 214 | 204 |
| Q2:Treatment improved ability to engage? No | 14 | 7 | 8 |
| Q2: Treatment improved ability to engage? No Respo | 29 | 36 | 49 |
The number of times participants switched erectile dysfunction medication within the 3 treatments being studied (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand).
| number of treatment switches | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Number of Treatment Switches | 1.2 ± 0.4 | 1.2 ± 0.5 | 1.3 ± 0.5 |
Results are reported as the number of participants per sequence of study medications (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) that were taken as a result of switching treatments. The Other Treatment Sequence reports the number of participants per sequence of study medications that were taken as a result of switching treatments more than once. The number of participants who did not switch is also reported.
| participants | Entire Study Population |
|---|---|
| No Treatment Intake | 3 |
| No Switch | 409 |
| From Once a Day to Any On Demand | 95 |
| From Any On Demand to Once a Day | 84 |
| From Any On Demand to Any On Demand | 97 |
| Returning Back to Randomized Treatment | 35 |
| Other Treatment Sequence | 47 |
The reported reasons for a decision to discontinue from initial randomized treatment prior to Week 24 are reported. Discontinuation of randomized treatment was defined as switching between the 3 study treatments (tadalafil on demand, tadalafil once a day, or sildenafil citrate on demand) or discontinuing from all treatments. A change of dose within the same treatment was not considered as switching of treatment.
| participants | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Slow onset of action | 5 | 9 | 10 |
| Completed treatment | 1 | 1 | 1 |
| Lack of efficacy (hardness of erection) | 46 | 55 | 55 |
| Lack of efficacy (duration of erection) | 7 | 11 | 24 |
| Lack of confidence in medication working each time | 3 | 5 | 2 |
| Adverse event | 7 | 10 | 16 |
| Feel medication controls my sexual life | 1 | 0 | 7 |
| Non-desired spontaneous erections | 2 | 4 | 0 |
| Time constraints due to short drug action window | 1 | 0 | 11 |
| Partner's request | 0 | 2 | 3 |
| Don't want to take a pill every day | 0 | 27 | 0 |
| Prefer a pill every day, not on demand | 20 | 0 | 28 |
| Participant discontinuation from the trial | 11 | 11 | 14 |
| Participant did not take any study drug | 2 | 0 | 1 |
| Participants without discontinuation event | 146 | 122 | 89 |
The differences in time between the 8-week time point and the discontinuation of all study treatments (that is, discontinuation from the study and not switching to another treatment) are reported by the median (95% confidence interval). Duration was measured as the number of days from Week 8 to the date of the last dose of the study drug. This outcome measure was estimated using the Kaplan-Meier product-limit method.
| days | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Number of Days From the 8-Week Study Visit to the Time the Participant Discontinues From All Phosphodiesterase Type 5 (PDE5) Inhibitor Treatments | NA (NA to NA) | NA (200 to NA) | 187 (165 to NA) |
Self-reported intercourse satisfaction score over past 4 weeks (1 intercourse attempt item, 2 intercourse satisfaction items). Each item range: 0 (no intercourse attempts/no satisfaction) to 5 (more attempts/high satisfaction). Total scores range: 0-15; lower scores=lower intercourse satisfaction. Least Squares Mean changes from baseline to endpoint for each visit from repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. Correlation matrix for repeated observations assumed to be unstructured.
| units on a scale | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Change from Baseline to Week 4 | 3.21 ± 0.20 | 3.22 ± 0.20 | 3.53 ± 0.20 |
| Change from Baseline to Week 8 (n=231, 232, 232) | 3.69 ± 0.20 | 3.15 ± 0.20 | 3.95 ± 0.20 |
| Change from Baseline to Week 16 (n=167, 146, 101) | 4.38 ± 0.20 | 3.60 ± 0.21 | 4.41 ± 0.23 |
| Change from Baseline to Week 24 (n=141, 116, 81) | 4.48 ± 0.21 | 3.71 ± 0.22 | 4.70 ± 0.24 |
Self-reported overall satisfaction on the IIEF over past 4 weeks and consists of 2 questions (items 13 and 14), each rated on a scale from 1 (very dissatisfied) to 5 (very satisfied). Total scores range from 2 to 10; lower numerical scores represent lower overall satisfaction. Least Squares Mean changes from baseline to endpoint for each visit were from a repeated measures analysis and included terms for baseline score, treatment group, country, baseline\*treatment (if p\<0.10), visit, and visit\*treatment. The correlation matrix for the repeated observations was assumed to be unstructured.
| units on a scale | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Change from Baseline to Week 4 | 2.46 ± 0.16 | 2.58 ± 0.15 | 2.72 ± 0.15 |
| Change from Baseline to Week 8 (n=230, 231, 233) | 2.80 ± 0.16 | 2.85 ± 0.16 | 2.98 ± 0.16 |
| Change from Baseline to Week 16 (n=167, 145, 101) | 3.34 ± 0.15 | 3.09 ± 0.15 | 3.48 ± 0.17 |
| Change from Baseline to Week 24 (n=141, 116, 81) | 3.50 ± 0.15 | 3.24 ± 0.16 | 3.41 ± 0.17 |
The participant questionnaire consists of 11 questions. Each question is rated on a scale of 0 (extremely low treatment satisfaction) to 4 (extremely high treatment satisfaction). The EDITS summary score was obtained by adding each individual result for all questions, dividing by the number of questions answered (mean satisfaction score), then multiplying by 25, thus obtaining a score range from 0 (extremely low treatment satisfaction) to 100 (extremely high satisfaction). Least Squares Mean changes were adjusted for treatment group, country, visit, and visit\*treatment.
| units on a scale | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| EDITS at Week 4 | 72.36 (69.64 to 75.08) | 75.20 (72.51 to 77.90) | 71.98 (69.28 to 74.67) |
| EDITS at Week 8 (n=231, 235, 231) | 75.28 (72.51 to 78.05) | 76.64 (73.88 to 79.39) | 72.74 (69.99 to 75.49) |
| EDITS at Week 16 (n=168, 147, 100) | 79.64 (77.00 to 82.29) | 77.66 (74.97 to 80.35) | 76.64 (73.71 to 79.56) |
| EDITS at Week 24 (n=141, 118, 80) | 81.01 (78.44 to 83.58) | 78.75 (76.10 to 81.41) | 77.98 (75.09 to 80.87) |
The PAIRS is a 23-item scale that assesses broader psychological/interpersonal outcomes associated with erectile dysfunction and its treatment. Each question is rated on a Likert scale from 1 (strongly disagree) to 4 (strongly agree). The scale consists of 3 domains: Sexual Self-Confidence (items 1-6), Spontaneity domain (items 7-15), and Time Concerns (items 16-23). The average domain score for each domain was calculated by adding the nonmissing items for the respective domain, then dividing by the number of nonmissing items for the respective domain. Each average domain score ranged from 1 to 4. Higher scores represent the following: greater sexual self-confidence (better outcome); greater spontaneity (better outcome); higher time concerns (worse outcome). The Least Squares Mean changes were adjusted for treatment group, country, baseline IIEF-EF severity, baseline domain score, and baseline domain score\*treatment (if p\<0.10).
| units on a scale | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Sexual Self-Confidence Domain (n=196, 203, 185) | 0.93 (0.83 to 1.03) | 0.90 (0.81 to 1.00) | 0.73 (0.64 to 0.83) |
| Spontaneity Domain (n=197, 202, 186) | 0.13 (0.07 to 0.20) | 0.11 (0.04 to 0.18) | 0.02 (-0.05 to 0.09) |
| Time Concerns Domain (n=196, 200, 184) | -0.08 (-0.16 to -0.01) | -0.20 (-0.27 to -0.12) | 0.04 (-0.03 to 0.12) |
SEAR assesses psychosocial outcomes in men with erectile dysfunction. Sexual Relationship domain consists of 8 items (items 1-8). Items 2-8 are rated on a scale of 1 (Never) to 5 (Always), whereas item 1 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. Transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes adjusted for baseline score, treatment group, country, visit, and visit\*treatment.
| units on a scale | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Change from Baseline to Week 4 | 27.65 (24.65 to 30.65) | 29.26 (26.29 to 32.23) | 29.50 (26.53 to 32.48) |
| Change from Baseline to Week 8 (n=230, 232, 231) | 31.42 (28.23 to 34.61) | 31.07 (27.90 to 34.24) | 31.15 (27.99 to 34.31) |
| Change from Baseline to Week 16 (n=167, 146, 101) | 37.59 (34.58 to 40.61) | 32.90 (29.84 to 35.96) | 37.32 (34.03 to 40.60) |
| Change from Baseline to Week 24 (n=140, 117, 81) | 39.37 (36.31 to 42.43) | 34.96 (31.79 to 38.13) | 37.46 (34.05 to 40.87) |
SEAR assesses psychosocial outcomes in men with erectile dysfunction. Confidence domain measures improvement in confidence; 2 subscales (6 items: Self-Esteem \[items 9-12\]; Overall Relationship \[items 13-14\]). Each item range: 1 (Never) to 5 (Always); item 11 reverse scored. Domain score=sum of domain's respective items, then transformed into 0 (least favorable) to 100 (most favorable) scale. Transformed score=100x\[(actual raw score-lowest possible raw score)/possible raw score range\]. Least Squares Mean change adjusted for baseline score, treatment group, country, visit, and visit\*treatment.
| units on a scale | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Change from Baseline to Week 4 | 23.43 (20.32 to 26.54) | 23.04 (19.96 to 26.13) | 25.03 (21.94 to 28.12) |
| Change from Baseline to Week 8 (n=230, 233, 232) | 26.97 (23.83 to 30.11) | 26.10 (22.97 to 29.22) | 27.14 (24.03 to 30.25) |
| Change from Baseline to Week 16 (n=167, 147, 100) | 33.15 (30.28 to 36.02) | 28.33 (25.41 to 31.25) | 31.86 (28.71 to 35.00) |
| Change from Baseline to Week 24 (n=140, 116, 81) | 33.74 (30.64 to 36.84) | 30.42 (27.21 to 33.63) | 31.66 (28.21 to 35.12) |
SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Self-Esteem domain consists of 4 items (items 9-12), each rated on a scale of 1 (Never) to 5 (Always). Item 11 is reverse scored (1=Always and 5=Never). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit\*treatment.
| units on a scale | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Change from Baseline to 4 Weeks | 25.18 (21.95 to 28.41) | 24.10 (20.90 to 27.30) | 26.59 (23.39 to 29.79) |
| Change from Baseline to 8 Weeks (n=230, 233, 233) | 29.14 (25.93 to 32.35) | 27.80 (24.60 to 30.99) | 28.92 (25.75 to 32.10) |
| Change from Baseline to 16 Weeks (n=167, 147, 100) | 35.23 (32.20 to 38.26) | 29.46 (26.37 to 32.55) | 33.85 (30.50 to 37.20) |
| Change from Baseline to 24 Weeks (n=140, 116, 81) | 35.86 (32.59 to 39.12) | 31.14 (27.75 to 34.52) | 33.52 (29.88 to 37.16) |
SEAR assesses psychosocial outcomes in men with erectile dysfunction. The Overall Relationship domain consists of 2 items (items 13-14), each rated on a scale of 1 (Never) to 5 (Always). The domain score was computed by summing its respective items, then transforming it into a 0 (least favorable) to 100 (most favorable) scale. The transformed score = 100 x \[(actual raw score - lowest possible raw score)/possible raw score range\]. Least Squares Mean changes were adjusted for baseline score, treatment group, country, visit, and visit\*treatment.
| units on a scale | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Change from Baseline to Week 4 | 19.92 (16.41 to 23.44) | 21.10 (17.63 to 24.57) | 22.00 (18.52 to 25.48) |
| Change from Baseline to Week 8 (n=229, 232, 232) | 22.75 (19.19 to 26.31) | 22.96 (19.43 to 26.50) | 23.74 (20.22 to 27.27) |
| Change from Baseline to Week 16 (n=166, 147, 100) | 29.63 (26.46 to 32.79) | 26.96 (23.74 to 30.17) | 28.57 (25.07 to 32.08) |
| Change from Baseline to Week 24 (n=139, 116, 81) | 30.28 (26.93 to 33.62) | 29.93 (26.43 to 33.43) | 28.74 (24.93 to 32.56) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tadalafil On Demand | — | 8/250 (3.2%) | 106/250 (42.4%) |
| Tadalafil Once a Day | — | 4/257 (1.6%) | 80/257 (31.1%) |
| Sildenafil Citrate On Demand | — | 2/260 (0.8%) | 103/260 (39.6%) |
| Event | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Infections and infestationsInfections and infestations | 2/250 | 0/257 | 0/260 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/250 | 1/257 | 1/260 |
| Congenital, familial and genetic disordersCongenital, familial and genetic disorders | 1/250 | 0/257 | 0/260 |
| Pulmonary sequestrationCongenital, familial and genetic disorders | 1/250 | 0/257 | 0/260 |
| DiverticulitisInfections and infestations | 1/250 | 0/257 | 0/260 |
| ParotitisInfections and infestations | 1/250 | 0/257 | 0/260 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/250 | 0/257 | 0/260 |
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 1/250 | 0/257 | 0/260 |
| Oesophageal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/250 | 0/257 | 0/260 |
| Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/250 | 0/257 | 0/260 |
| Event | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand |
|---|---|---|---|
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 44/250 | 19/257 | 40/260 |
| Gastrointestinal disordersGastrointestinal disorders | 21/250 | 30/257 | 10/260 |
| Nervous system disordersNervous system disorders | 14/250 | 19/257 | 27/260 |
| OverdoseInjury, poisoning and procedural complications | 21/250 | 8/257 | 23/260 |
| HeadacheNervous system disorders | 10/250 | 14/257 | 23/260 |
| Infections and infestationsInfections and infestations | 17/250 | 10/257 | 10/260 |
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 16/250 | 17/257 | 9/260 |
| Vascular disordersVascular disorders | 11/250 | 3/257 | 17/260 |
| Intentional overdoseInjury, poisoning and procedural complications | 16/250 | 5/257 | 8/260 |
| Age Continuous(years) | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand | Total |
|---|---|---|---|---|
| Mean | 53.2 ± 11.57 | 52.9 ± 11.69 | 53.0 ± 11.76 | 53.0 ± 11.66 |
| Sex: Female, Male(Participants) | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 252 | 257 | 261 | 770 |
| Race (NIH/OMB)(Participants) | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 4 | 10 |
| White | 248 | 251 | 254 | 753 |
| More than one race | 0 | 0 | 1 | 1 |
| Unknown or Not Reported | 2 | 2 | 2 | 6 |
| Region of Enrollment(participants) | Tadalafil On Demand | Tadalafil Once a Day | Sildenafil Citrate On Demand | Total |
|---|---|---|---|---|
| Portugal | 6 | 5 | 7 | 18 |
| France | 99 | 102 | 100 | 301 |
| Greece | 9 | 8 | 9 | 26 |
| Poland | 15 | 16 | 16 | 47 |
| Spain | 48 | 49 | 52 | 149 |
| Romania | 20 | 22 | 21 | 63 |
| Germany | 45 | 45 | 47 | 137 |
| United Kingdom | 10 | 10 | 9 | 29 |
The record gives a start of May 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil